The first patient has been dosed in a P-Ib/IIa trial evaluating bemcentinib + pembrolizumab and doublet CT in patients with NSCLC harboring STK11 mutations (STK11m)
The P-Ib portion of the study will evaluate the safety and feasibility of bemcentinib + pembrolizumab and doublet CT in 1L advanced/metastatic non-sq. NSCLC patients, regardless of STK11 status while the P-IIa expansion part will assess the efficacy in patients with STK11 mutations
Bemcentinib is a potent selective small molecule inhibitor of Axl over-expressed in many metastatic solid tumors and has been identified as a marker of a poor prognosis in patients with NSCLC & showed synergistic activity with docetaxel in vivo models of NSCLC
Ref: PRNewswire | Image: BerGenBio
Related News:- BerGenBio Reports P-II Trial Results of BGB324 (bemcentinib) as 2L Treatment of Non-Small Cell Lung Cancer
